Yun Zhong
Stock Analyst at Wedbush
(3.59)
# 990
Out of 5,182 analysts
53
Total ratings
54.35%
Success rate
6.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PASG Passage Bio | Downgrades: Neutral | $32 → $8 | $5.78 | +38.41% | 4 | Apr 21, 2026 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $273 | $222.08 | +22.93% | 5 | Apr 9, 2026 | |
| RZLT Rezolute | Upgrades: Outperform | $2 → $5 | $3.07 | +62.87% | 3 | Mar 25, 2026 | |
| IRD Opus Genetics | Maintains: Outperform | $8 → $10 | $5.00 | +100.00% | 2 | Mar 12, 2026 | |
| WVE Wave Life Sciences | Maintains: Outperform | $33 → $35 | $7.52 | +365.43% | 4 | Mar 6, 2026 | |
| MNKD MannKind | Maintains: Outperform | $10 → $8 | $2.79 | +186.74% | 1 | Mar 5, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $32 → $34 | $21.07 | +61.37% | 13 | Jan 23, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $11.37 | +40.72% | 3 | Nov 6, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $70 → $86 | $101.21 | -15.03% | 3 | Oct 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $16.66 | +8.04% | 2 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $8.75 | +220.00% | 1 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $3.77 | +112.20% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.32 | +85.19% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $3.43 | +832.94% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $3.37 | +730.86% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.30 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $14.49 | +10.42% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $18.05 | +154.85% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.28 | +3,493.24% | 1 | May 5, 2021 |
Passage Bio
Apr 21, 2026
Downgrades: Neutral
Price Target: $32 → $8
Current: $5.78
Upside: +38.41%
Ascendis Pharma
Apr 9, 2026
Reiterates: Outperform
Price Target: $273
Current: $222.08
Upside: +22.93%
Rezolute
Mar 25, 2026
Upgrades: Outperform
Price Target: $2 → $5
Current: $3.07
Upside: +62.87%
Opus Genetics
Mar 12, 2026
Maintains: Outperform
Price Target: $8 → $10
Current: $5.00
Upside: +100.00%
Wave Life Sciences
Mar 6, 2026
Maintains: Outperform
Price Target: $33 → $35
Current: $7.52
Upside: +365.43%
MannKind
Mar 5, 2026
Maintains: Outperform
Price Target: $10 → $8
Current: $2.79
Upside: +186.74%
Sarepta Therapeutics
Jan 23, 2026
Maintains: Outperform
Price Target: $32 → $34
Current: $21.07
Upside: +61.37%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $11.37
Upside: +40.72%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Outperform
Price Target: $70 → $86
Current: $101.21
Upside: -15.03%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $16.66
Upside: +8.04%
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $8.75
Upside: +220.00%
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $3.77
Upside: +112.20%
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $4.32
Upside: +85.19%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.43
Upside: +832.94%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $3.37
Upside: +730.86%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $6.30
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $14.49
Upside: +10.42%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $18.05
Upside: +154.85%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.28
Upside: +3,493.24%